Current management of Hodgkin's disease.
The accepted management of Hodgkin's disease has changed markedly in the past two decades. It should be considered a tumor of unifocal origin and potentially one of the most curable cancers, given early diagnosis, careful evaluation, meticulously accurate staging and aggressive, radical treatment. This requires a team effort, is tedious and expensive, and morbidity and mortality remain significant, but the high yield of long remissions and apparent cures justifies this approach to the problem.
D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D009588:Nitrogen Mustard Compounds; D011344:Procarbazine; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone